HLN
Haleon Plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$9.39
+2.18%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
ValuationView details →
P/E (Fwd)
20.6x
EV/EBITDA
13.2x
Market Cap
$41.29B
MomentumView details →
1D Return
+2.18%
YTD Return
−7.27%
RSI (14)
38.1
ValuationView details →
P/E (Fwd)
20.6x
EV/EBITDA
13.2x
Market Cap
$41.29B
RSI (14)
38.1
MomentumView details →
1D Return
+2.18%
YTD Return
−7.27%
SummaryUpdated Jun 1, 2026
Haleon plc (LSE:HLN) is a British multinational consumer healthcare company that was spun off from GlaxoSmithKline in July 2022, making it one of the world's largest standalone consumer healthcare companies. The company was formed through the demerger of GSK's consumer healthcare division, which had been built over decades through acquisitions and internal development. Headquartered in Brentford, United Kingdom, Haleon operates globally across North America, Europe, Middle East, Africa, Latin America, and Asia Pacific, managing a portfolio of well-established consumer health brands that reach millions of consumers daily.
Similar companies
Latest newsMore news →
Haleon secured improved shelf placement agreements with U.S. retailers Walmart and Target to increase product visibility and market share.12d agoHaleon's antacid brand ENO launched a new advertising campaign in India, 'Acidity ke kayi naam, ENO sab par kare kaam', to educate consumers about acidity-related symptoms.29d ago